In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories

Investing In People: Aligning VCs And Today’s Entrepreneurs

In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.

Business Strategies C-Suite Speaks

Science Matters: Targeting Heme Trafficking In A Variety Of Diseases

A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.

Research and Development Strategies Research & Development Innovation

Meindert Boysen On What Companies Should Expect From NICE

In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.

Market Access Pricing Strategies Reimbursement

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development

Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Recent Issues

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

2020 Could Spell The End Of Mega-Mergers, For Now

Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.

Business Strategies Commercial

The Only Way Is Nasdaq – Part Two

It has been a bumpy ride for some of the (still modest) number of European biotechs listed on Nasdaq, for various reasons. Yet most expect the direct-to-Nasdaq trend to continue. Europe’s public markets simply cannot compete.

Business Strategies C-Suite Speaks

The Only Way Is Nasdaq – Part One

The US Nasdaq exchange has become the only option for ambitious UK and European biotechs.

Business Strategies C-Suite Speaks

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Differentiating In Logistics For Regenerative Medicine’s Exploding Universe

Cryoport is a unique company in its niche – supporting regenerative medicine clinical trials and commercial products with cold chain logistics – and has designs on becoming a full supply chain partner for the biopharma industry. CEO Jerry Shelton explained the company’s current role and future plans to In Vivo during the recent Jefferies Healthcare conference.

Innovation Medical Device

Regular Acceptance Of Simulation Studies More Likely In 2020s

Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.

Artificial Intelligence Clinical Trials

CNS Biomarkers: Monument Targets Schizophrenia, Anxiety And Cognitive Decline

Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.

BioPharmaceutical C-Suite Speaks

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Creating Stability In A Time Of Transition

UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.

Leadership Financing

Execs On The Move, February 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Companies

Investing In People: Aligning VCs And Today’s Entrepreneurs

In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.

Business Strategies C-Suite Speaks

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Analyzing An EU Medtech Regulation Crisis In The Making

EU medical device consultant Trevor Lewis takes note of the recent, if belated, progress towards the building of the post-MDR playing field for medical device companies in Europe, but calls political decision-makers and economic operators to account: getting it right is nothing short of a matter of life and death, he tells In Vivo.

EU Market Access

New Business Models Are Needed To Support Innovative Payer Partnerships

Maximizing patient access to innovative and effective treatments will require increased transparency, improved outcomes data analyses, dynamic contract management and perhaps most importantly, good faith on both sides.

Market Access Pricing Strategies

Mehta Analysis: The New Decade Is Sure to Transform Biopharma Globally

Industry has the tools to bring more and far better treatments to more people faster than ever, with much lower R&D cost and very little selling needed for these targeted therapies – a perfect prescription for slashing prices for global access while preserving profits, argues Viren Mehta of Mehta Partners LLC.

Business Strategies Research and Development Strategies

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals Shaping The Medical Industry, February 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.

Deals Financing

Biopharma Quarterly Dealmaking Statistics, Q4 2019

Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.
Deals Market Intelligence

Deals In Depth: December 2019

Gene therapy dominated the top December deals, with a $2.9bn alliance between Roche and Saretpta for DMD treatment SRP9001, and Astellas's $3bn acquisition of Audentes Therapeutics. Follow-on public offerings made up close to or more than half of both biopharma and device financing.

BioPharmaceutical Medical Device
UsernamePublicRestriction

Register